Lahore: Ferozsons Laboratories Limited reported a robust financial performance for the three months ending September 30, 2026, as disclosed in their recently released unaudited interim financial results. According to the report dated October 30, 2026, the company's consolidated revenue for the period reached Rs. 7.07 billion, marking a 19% increase compared to the same period last year.

The company's standalone financial performance also demonstrated significant growth, with net sales closing at Rs. 4.77 billion, a 23% rise over the previous year. The consolidated gross profit for the period was reported at Rs. 3.24 billion, while the standalone gross profit stood at Rs. 1.95 billion. Both figures reflect a maintained gross profit margin of 41%, consistent with the prior year.

According to information available from the Pakistan Stock Exchange (PSX), Ferozsons Laboratories' consolidated profit before tax increased to Rs. 637 million from Rs. 539 million, and profit after tax rose to Rs. 396 million from Rs. 322 million. The company's earnings per share on a standalone basis improved to Rs. 5.05 from Rs. 4.20.

The company's growth was primarily driven by a 32% increase in in-market generic sales and a 25% increase in institutional sales of generics and medical devices. However, export sales suffered a significant decline of 51%, attributed to the closure of the Pakistan-Afghanistan border.

The financial report also highlighted an increase in selling and distribution expenses by 30%, which was mainly due to the expansion of the company's field force and enhanced field activities, while administrative expenses and finance costs remained largely unchanged.

The subsidiary company, BF Biosciences Limited, which is 57.36% owned by Ferozsons, recorded sales of Rs. 2.78 billion, reflecting a 14% growth from the previous year. The subsidiary's profit after tax increased by 16%, closing at Rs. 185 million compared to Rs. 160 million in the same period last year. For further details, stakeholders are referred to the subsidiary's published financial statements for the period ended September 30, 2026, under the designated market category PSX: BFBIO.

Overall, Ferozsons Laboratories Limited's financial results for the quarter indicate a strong performance, notwithstanding challenges in the export sector.